News

News Subscription

Aug 07. 2020
Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in China
Read more
Download
Jul 28. 2020
Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond
Read more Download
Jul 28. 2020
Basilea announces data presentations at ESMO Virtual Congress 2020
Read more
Download
Jul 21. 2020
Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance of tendered Bonds in an aggregated principal amount of approximately CHF 47 million
Read more Download
Jul 20. 2020
Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA)
Read more
Download
Jul 17. 2020
Basilea continues with the implementation of the Repurchase Offer and the issuance of New Bonds
Read more Download
Jul 17. 2020
Basilea Bonds tendered in an aggregate principal amount of approximately CHF 47 million
Read more Download
Jul 15. 2020
Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific
Read more
Download
Jul 10. 2020
Basilea announces the start of the offer period of its partial repurchase offer for its outstanding convertible bonds due 2022
Read more Download
Jun 30. 2020
Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022
Read more
Download